2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS

2CDA 在复发/缓解多发性硬化症中的作用

• 批准号: 6307349
• 负责人: JACK C SIPE
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307349
• 关键词: chlorodeoxyadenosine; clinical research; clinical trials; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; magnetic resonance imaging; multiple sclerosis; nervous system disorder chemotherapy; relapse /recurrence

Multiple sclerosis (MS) is a progressive neurologic disorder that is likely to have an autoimmune basis. We have been testing the safety and efficacy of cladribine (2-CdA) as a treatment for MS. Other current treatments are unsatisfactory, with Beta Interferon and Copaxone having a partial effect on relapses in MS.

多发性硬化症（MS）是一种进行性神经系统疾病，可能具有自身免疫性的基础。 我们一直在测试甲别宾（2-CDA）作为MS的治疗方法的安全性和功效。 当前的其他治疗方法不令人满意，β干扰素和Copaxone对MS中的复发有部分影响。